 Kelly Knupp
Concepts (274)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Spasms, Infantile | 25 | 2024 | 122 | 7.450 |
Why?
| | Epilepsies, Myoclonic | 28 | 2025 | 51 | 6.720 |
Why?
| | Anticonvulsants | 32 | 2025 | 216 | 6.470 |
Why?
| | Lennox Gastaut Syndrome | 7 | 2024 | 17 | 3.580 |
Why?
| | Epilepsy | 18 | 2024 | 332 | 3.360 |
Why?
| | Vigabatrin | 9 | 2022 | 18 | 2.620 |
Why?
| | Adrenocorticotropic Hormone | 7 | 2020 | 141 | 2.430 |
Why?
| | Seizures | 26 | 2025 | 430 | 1.950 |
Why?
| | Electroencephalography | 12 | 2024 | 433 | 1.770 |
Why?
| | Drug Resistant Epilepsy | 8 | 2025 | 102 | 1.610 |
Why?
| | Epilepsies, Partial | 4 | 2025 | 50 | 1.350 |
Why?
| | Epilepsy, Generalized | 3 | 2023 | 19 | 1.150 |
Why?
| | Fenfluramine | 8 | 2024 | 14 | 1.090 |
Why?
| | Glucocorticoids | 3 | 2020 | 596 | 1.050 |
Why?
| | Delphi Technique | 3 | 2024 | 273 | 1.020 |
Why?
| | Developmental Disabilities | 5 | 2025 | 264 | 1.020 |
Why?
| | Plant Extracts | 4 | 2020 | 200 | 0.920 |
Why?
| | Cannabidiol | 4 | 2022 | 119 | 0.900 |
Why?
| | NAV1.6 Voltage-Gated Sodium Channel | 1 | 2024 | 11 | 0.900 |
Why?
| | Infant | 32 | 2025 | 9442 | 0.890 |
Why?
| | Prednisolone | 4 | 2020 | 83 | 0.860 |
Why?
| | Status Epilepticus | 5 | 2024 | 50 | 0.810 |
Why?
| | Genetic Therapy | 2 | 2023 | 296 | 0.800 |
Why?
| | Child | 44 | 2025 | 21968 | 0.720 |
Why?
| | Child, Preschool | 27 | 2025 | 11069 | 0.710 |
Why?
| | Sleep | 4 | 2024 | 751 | 0.700 |
Why?
| | Medical Marijuana | 2 | 2019 | 117 | 0.690 |
Why?
| | Dioxolanes | 2 | 2020 | 6 | 0.670 |
Why?
| | Humans | 82 | 2025 | 136783 | 0.660 |
Why?
| | Leukomalacia, Periventricular | 1 | 2017 | 8 | 0.560 |
Why?
| | Caregivers | 6 | 2025 | 873 | 0.540 |
Why?
| | Precision Medicine | 1 | 2021 | 426 | 0.540 |
Why?
| | Thyrotropin | 1 | 2017 | 114 | 0.540 |
Why?
| | Treatment Outcome | 17 | 2025 | 10764 | 0.500 |
Why?
| | Infant, Premature, Diseases | 1 | 2017 | 100 | 0.500 |
Why?
| | Cannabis | 3 | 2020 | 488 | 0.480 |
Why?
| | Treatment Failure | 1 | 2016 | 353 | 0.480 |
Why?
| | Male | 45 | 2025 | 67361 | 0.480 |
Why?
| | Insulin-Like Growth Factor I | 1 | 2017 | 316 | 0.470 |
Why?
| | Adolescent | 25 | 2025 | 21463 | 0.460 |
Why?
| | Perception | 1 | 2017 | 356 | 0.450 |
Why?
| | Unverricht-Lundborg Syndrome | 1 | 2014 | 1 | 0.440 |
Why?
| | Lafora Disease | 1 | 2014 | 2 | 0.440 |
Why?
| | Female | 45 | 2025 | 72840 | 0.440 |
Why?
| | Testosterone | 1 | 2017 | 401 | 0.420 |
Why?
| | Migraine Disorders | 2 | 2024 | 103 | 0.420 |
Why?
| | Epilepsy, Absence | 2 | 2023 | 9 | 0.420 |
Why?
| | Disease Progression | 2 | 2021 | 2750 | 0.420 |
Why?
| | Myoclonus | 2 | 2023 | 15 | 0.420 |
Why?
| | Administration, Oral | 5 | 2019 | 808 | 0.410 |
Why?
| | Physicians | 1 | 2021 | 897 | 0.400 |
Why?
| | Practice Guidelines as Topic | 2 | 2020 | 1568 | 0.400 |
Why?
| | Adrenal Cortex Hormones | 1 | 2016 | 551 | 0.380 |
Why?
| | Epileptic Syndromes | 5 | 2024 | 84 | 0.370 |
Why?
| | NAV1.1 Voltage-Gated Sodium Channel | 4 | 2023 | 17 | 0.370 |
Why?
| | Cost of Illness | 3 | 2018 | 300 | 0.350 |
Why?
| | Pneumonia, Viral | 3 | 2020 | 368 | 0.350 |
Why?
| | Coronavirus Infections | 3 | 2020 | 359 | 0.350 |
Why?
| | Prospective Studies | 11 | 2023 | 7583 | 0.340 |
Why?
| | Hypertension | 1 | 2019 | 1284 | 0.340 |
Why?
| | Parents | 3 | 2022 | 1355 | 0.340 |
Why?
| | Retrospective Studies | 14 | 2025 | 15564 | 0.330 |
Why?
| | Consensus | 4 | 2024 | 679 | 0.300 |
Why?
| | Pandemics | 4 | 2022 | 1619 | 0.300 |
Why?
| | Dronabinol | 3 | 2022 | 229 | 0.300 |
Why?
| | Executive Function | 2 | 2024 | 448 | 0.290 |
Why?
| | Cannabinoids | 2 | 2022 | 161 | 0.280 |
Why?
| | Genetic Testing | 2 | 2023 | 452 | 0.280 |
Why?
| | Cohort Studies | 7 | 2024 | 5718 | 0.260 |
Why?
| | Biological Ontologies | 1 | 2025 | 19 | 0.240 |
Why?
| | Headache | 1 | 2006 | 151 | 0.230 |
Why?
| | Diet, Ketogenic | 1 | 2025 | 37 | 0.230 |
Why?
| | Seizures, Febrile | 1 | 2024 | 21 | 0.230 |
Why?
| | Dichloroacetic Acid | 1 | 2024 | 8 | 0.230 |
Why?
| | Vagus Nerve Stimulation | 1 | 2024 | 29 | 0.220 |
Why?
| | Acidosis, Lactic | 1 | 2024 | 46 | 0.220 |
Why?
| | Delivery of Health Care | 3 | 2020 | 939 | 0.220 |
Why?
| | Analgesics | 1 | 2006 | 205 | 0.220 |
Why?
| | Natural Language Processing | 1 | 2025 | 93 | 0.210 |
Why?
| | Epilepsy, Reflex | 1 | 2023 | 1 | 0.210 |
Why?
| | Comorbidity | 2 | 2019 | 1611 | 0.210 |
Why?
| | Betacoronavirus | 3 | 2020 | 267 | 0.200 |
Why?
| | Video Recording | 1 | 2024 | 181 | 0.200 |
Why?
| | Wakefulness | 1 | 2024 | 125 | 0.200 |
Why?
| | Family | 2 | 2018 | 666 | 0.200 |
Why?
| | Neuropsychological Tests | 2 | 2025 | 1054 | 0.200 |
Why?
| | Young Adult | 8 | 2025 | 13126 | 0.200 |
Why?
| | Lymphocytes | 1 | 2025 | 395 | 0.200 |
Why?
| | Double-Blind Method | 3 | 2022 | 1981 | 0.190 |
Why?
| | Cosyntropin | 1 | 2022 | 5 | 0.190 |
Why?
| | Quality of Life | 4 | 2024 | 2868 | 0.190 |
Why?
| | Spasm | 1 | 2022 | 20 | 0.190 |
Why?
| | Sodium Channel Blockers | 1 | 2021 | 24 | 0.180 |
Why?
| | Outpatients | 1 | 2025 | 393 | 0.180 |
Why?
| | Benzazepines | 2 | 2018 | 39 | 0.180 |
Why?
| | Delayed Diagnosis | 1 | 2021 | 91 | 0.180 |
Why?
| | Oligonucleotides, Antisense | 1 | 2021 | 111 | 0.180 |
Why?
| | Dependovirus | 1 | 2021 | 68 | 0.180 |
Why?
| | Shab Potassium Channels | 1 | 2020 | 18 | 0.170 |
Why?
| | KCNQ2 Potassium Channel | 1 | 2020 | 10 | 0.170 |
Why?
| | Adult | 11 | 2025 | 37616 | 0.170 |
Why?
| | Machine Learning | 1 | 2025 | 487 | 0.160 |
Why?
| | Standard of Care | 1 | 2020 | 73 | 0.160 |
Why?
| | Cognition | 2 | 2025 | 1166 | 0.160 |
Why?
| | Infant, Newborn | 7 | 2024 | 6046 | 0.160 |
Why?
| | Internationality | 1 | 2020 | 155 | 0.160 |
Why?
| | Causality | 1 | 2019 | 127 | 0.160 |
Why?
| | Hormones | 1 | 2019 | 142 | 0.150 |
Why?
| | Eyelids | 3 | 2023 | 37 | 0.150 |
Why?
| | Drug Approval | 1 | 2019 | 87 | 0.150 |
Why?
| | Tandem Mass Spectrometry | 2 | 2022 | 532 | 0.150 |
Why?
| | Mutation | 3 | 2023 | 3953 | 0.150 |
Why?
| | Health Surveys | 2 | 2018 | 517 | 0.150 |
Why?
| | Phenobarbital | 1 | 2018 | 19 | 0.150 |
Why?
| | Mitochondria | 1 | 2025 | 946 | 0.150 |
Why?
| | Health Care Surveys | 1 | 2020 | 563 | 0.150 |
Why?
| | Sickness Impact Profile | 1 | 2018 | 56 | 0.140 |
Why?
| | Animals | 6 | 2021 | 36768 | 0.140 |
Why?
| | United States | 7 | 2019 | 14660 | 0.140 |
Why?
| | Incidence | 2 | 2019 | 2788 | 0.140 |
Why?
| | Urine | 1 | 2017 | 55 | 0.140 |
Why?
| | Heterogeneous-Nuclear Ribonucleoprotein U | 1 | 2017 | 7 | 0.140 |
Why?
| | Body Height | 1 | 2017 | 199 | 0.130 |
Why?
| | Brain | 3 | 2018 | 2669 | 0.130 |
Why?
| | Surveys and Questionnaires | 4 | 2021 | 5749 | 0.130 |
Why?
| | Neuroimaging | 1 | 2018 | 263 | 0.130 |
Why?
| | Heterozygote | 1 | 2017 | 292 | 0.130 |
Why?
| | Employment | 1 | 2018 | 177 | 0.120 |
Why?
| | Plasma | 1 | 2017 | 213 | 0.120 |
Why?
| | Benzimidazoles | 1 | 2017 | 168 | 0.120 |
Why?
| | Intellectual Disability | 1 | 2017 | 163 | 0.120 |
Why?
| | Combined Modality Therapy | 1 | 2018 | 1235 | 0.120 |
Why?
| | Health Care Costs | 1 | 2018 | 385 | 0.110 |
Why?
| | Serotonin | 1 | 2017 | 323 | 0.110 |
Why?
| | Telemedicine | 2 | 2020 | 847 | 0.110 |
Why?
| | Neurology | 3 | 2020 | 114 | 0.110 |
Why?
| | Kaplan-Meier Estimate | 1 | 2016 | 891 | 0.110 |
Why?
| | Nervous System Diseases | 1 | 2017 | 265 | 0.110 |
Why?
| | Guideline Adherence | 1 | 2018 | 543 | 0.110 |
Why?
| | Follow-Up Studies | 3 | 2018 | 5115 | 0.110 |
Why?
| | Neurosurgical Procedures | 1 | 2015 | 197 | 0.100 |
Why?
| | Body Weight | 1 | 2017 | 981 | 0.100 |
Why?
| | Infant, Premature | 1 | 2017 | 567 | 0.100 |
Why?
| | Colorado | 2 | 2019 | 4491 | 0.100 |
Why?
| | Pentobarbital | 1 | 2011 | 16 | 0.090 |
Why?
| | Communication | 3 | 2024 | 869 | 0.090 |
Why?
| | Age of Onset | 3 | 2018 | 518 | 0.090 |
Why?
| | Observational Studies as Topic | 2 | 2024 | 116 | 0.090 |
Why?
| | Mental Health | 1 | 2018 | 721 | 0.090 |
Why?
| | Patient Acceptance of Health Care | 1 | 2018 | 806 | 0.090 |
Why?
| | Neurologists | 2 | 2021 | 21 | 0.090 |
Why?
| | Research Design | 1 | 2017 | 1107 | 0.090 |
Why?
| | Piracetam | 1 | 2010 | 13 | 0.090 |
Why?
| | Biomedical Research | 1 | 2017 | 689 | 0.080 |
Why?
| | Emergency Service, Hospital | 1 | 2021 | 2050 | 0.080 |
Why?
| | Limit of Detection | 2 | 2022 | 86 | 0.080 |
Why?
| | Hypnotics and Sedatives | 1 | 2011 | 199 | 0.080 |
Why?
| | Forecasting | 2 | 2024 | 384 | 0.080 |
Why?
| | Prevalence | 1 | 2016 | 2712 | 0.080 |
Why?
| | Health Resources | 2 | 2020 | 122 | 0.070 |
Why?
| | Middle Aged | 6 | 2025 | 33200 | 0.070 |
Why?
| | Drug Therapy, Combination | 2 | 2020 | 1059 | 0.060 |
Why?
| | Dopamine Uptake Inhibitors | 1 | 2005 | 59 | 0.060 |
Why?
| | Membrane Potential, Mitochondrial | 1 | 2025 | 71 | 0.060 |
Why?
| | Maternal Behavior | 1 | 2005 | 77 | 0.060 |
Why?
| | Pyruvate Dehydrogenase (Lipoamide) | 1 | 2024 | 10 | 0.060 |
Why?
| | Cell Respiration | 1 | 2025 | 102 | 0.060 |
Why?
| | Oxytocin | 1 | 2005 | 51 | 0.060 |
Why?
| | Multivariate Analysis | 2 | 2019 | 1513 | 0.060 |
Why?
| | Diagnosis, Differential | 2 | 2006 | 1483 | 0.060 |
Why?
| | Disease Management | 2 | 2020 | 623 | 0.060 |
Why?
| | Rare Diseases | 1 | 2025 | 101 | 0.060 |
Why?
| | Heredodegenerative Disorders, Nervous System | 1 | 2004 | 2 | 0.050 |
Why?
| | Intranuclear Inclusion Bodies | 1 | 2004 | 3 | 0.050 |
Why?
| | Hyalin | 1 | 2004 | 6 | 0.050 |
Why?
| | Wechsler Scales | 1 | 2024 | 55 | 0.050 |
Why?
| | Syncope | 1 | 2024 | 52 | 0.050 |
Why?
| | Introns | 1 | 2024 | 256 | 0.050 |
Why?
| | Aggression | 1 | 2005 | 204 | 0.050 |
Why?
| | Signal Transduction | 1 | 2017 | 5065 | 0.050 |
Why?
| | Postoperative Complications | 1 | 2015 | 2624 | 0.050 |
Why?
| | Mutation, Missense | 1 | 2025 | 338 | 0.050 |
Why?
| | Phenotype | 2 | 2025 | 3199 | 0.050 |
Why?
| | Rectum | 1 | 2004 | 185 | 0.050 |
Why?
| | Fatty Acids | 1 | 2025 | 444 | 0.050 |
Why?
| | Oxygen Consumption | 1 | 2025 | 696 | 0.050 |
Why?
| | Magnetic Resonance Imaging | 3 | 2020 | 3566 | 0.050 |
Why?
| | Pediatrics | 2 | 2020 | 1112 | 0.050 |
Why?
| | Risk Factors | 1 | 2016 | 10331 | 0.050 |
Why?
| | Interviews as Topic | 1 | 2024 | 766 | 0.050 |
Why?
| | Eosinophils | 1 | 2004 | 331 | 0.040 |
Why?
| | Inpatients | 1 | 2025 | 499 | 0.040 |
Why?
| | Health Services | 1 | 2021 | 103 | 0.040 |
Why?
| | Chromatography, Liquid | 1 | 2022 | 432 | 0.040 |
Why?
| | Adaptation, Psychological | 1 | 2025 | 651 | 0.040 |
Why?
| | Videoconferencing | 1 | 2020 | 66 | 0.040 |
Why?
| | Internet | 1 | 2024 | 648 | 0.040 |
Why?
| | Tuberous Sclerosis | 1 | 2020 | 55 | 0.040 |
Why?
| | Pilot Projects | 1 | 2025 | 1697 | 0.040 |
Why?
| | Placebos | 1 | 2019 | 197 | 0.040 |
Why?
| | Cell Line | 1 | 2025 | 2836 | 0.040 |
Why?
| | Metabolic Clearance Rate | 1 | 2019 | 116 | 0.040 |
Why?
| | Half-Life | 1 | 2019 | 165 | 0.040 |
Why?
| | Biological Availability | 1 | 2019 | 147 | 0.040 |
Why?
| | Cross-Sectional Studies | 2 | 2020 | 5417 | 0.040 |
Why?
| | Energy Metabolism | 1 | 2025 | 918 | 0.040 |
Why?
| | Pediatricians | 1 | 2020 | 129 | 0.040 |
Why?
| | Drug Resistance | 1 | 2019 | 169 | 0.040 |
Why?
| | Tissue Distribution | 1 | 2019 | 329 | 0.040 |
Why?
| | Intestinal Mucosa | 1 | 2004 | 620 | 0.040 |
Why?
| | Critical Illness | 1 | 2024 | 807 | 0.040 |
Why?
| | Neurologic Examination | 2 | 2011 | 113 | 0.040 |
Why?
| | Gene Ontology | 1 | 2018 | 53 | 0.040 |
Why?
| | Preexisting Condition Coverage | 1 | 2017 | 3 | 0.040 |
Why?
| | Atmospheric Pressure | 1 | 2017 | 23 | 0.040 |
Why?
| | Qualitative Research | 1 | 2025 | 1359 | 0.040 |
Why?
| | Proteomics | 1 | 2024 | 1108 | 0.030 |
Why?
| | Agenesis of Corpus Callosum | 1 | 2017 | 12 | 0.030 |
Why?
| | Waiting Lists | 1 | 2019 | 262 | 0.030 |
Why?
| | Efficiency | 1 | 2018 | 98 | 0.030 |
Why?
| | Ribonucleoproteins, Small Nuclear | 1 | 2017 | 24 | 0.030 |
Why?
| | Muscle Hypotonia | 1 | 2017 | 33 | 0.030 |
Why?
| | Receptors, Serotonin | 1 | 2017 | 34 | 0.030 |
Why?
| | Medicaid | 1 | 2021 | 433 | 0.030 |
Why?
| | Global Health | 1 | 2020 | 386 | 0.030 |
Why?
| | Chromosomes, Human, Pair 1 | 1 | 2017 | 72 | 0.030 |
Why?
| | Drug Costs | 1 | 2018 | 106 | 0.030 |
Why?
| | Chromosome Deletion | 1 | 2017 | 115 | 0.030 |
Why?
| | Income | 1 | 2018 | 200 | 0.030 |
Why?
| | Microcephaly | 1 | 2017 | 98 | 0.030 |
Why?
| | Animals, Genetically Modified | 1 | 2017 | 240 | 0.030 |
Why?
| | Larva | 1 | 2017 | 221 | 0.030 |
Why?
| | Drug Prescriptions | 1 | 2018 | 247 | 0.030 |
Why?
| | RNA Splicing | 1 | 2017 | 268 | 0.030 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2017 | 591 | 0.030 |
Why?
| | Central Nervous System | 1 | 2017 | 258 | 0.030 |
Why?
| | Gestational Age | 1 | 2018 | 902 | 0.030 |
Why?
| | Positron-Emission Tomography | 1 | 2015 | 295 | 0.030 |
Why?
| | Vaccination | 1 | 2022 | 1378 | 0.030 |
Why?
| | Zebrafish | 1 | 2017 | 495 | 0.020 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2017 | 856 | 0.020 |
Why?
| | Genetic Variation | 1 | 2017 | 985 | 0.020 |
Why?
| | Sex Factors | 1 | 2017 | 2068 | 0.020 |
Why?
| | Infusions, Intravenous | 1 | 2011 | 408 | 0.020 |
Why?
| | Protein Binding | 1 | 2017 | 2223 | 0.020 |
Why?
| | Prognosis | 1 | 2019 | 4018 | 0.020 |
Why?
| | Injections, Intravenous | 1 | 2010 | 205 | 0.020 |
Why?
| | Drug Administration Schedule | 1 | 2011 | 783 | 0.020 |
Why?
| | Kidney | 1 | 2017 | 1463 | 0.020 |
Why?
| | Genetic Predisposition to Disease | 1 | 2017 | 2417 | 0.020 |
Why?
| | Depression | 1 | 2018 | 1402 | 0.020 |
Why?
| | Obesity | 1 | 2021 | 2975 | 0.020 |
Why?
| | Hospitalization | 1 | 2018 | 2195 | 0.020 |
Why?
| | Acute Disease | 1 | 2010 | 1006 | 0.020 |
Why?
| | Disease Models, Animal | 1 | 2017 | 4279 | 0.020 |
Why?
| | Nalidixic Acid | 1 | 2005 | 1 | 0.020 |
Why?
| | Naphthyridines | 1 | 2005 | 19 | 0.020 |
Why?
| | Fluoxetine | 1 | 2005 | 54 | 0.010 |
Why?
| | Tomography, X-Ray Computed | 1 | 2015 | 2677 | 0.010 |
Why?
| | Drug Synergism | 1 | 2005 | 378 | 0.010 |
Why?
| | Submucous Plexus | 1 | 2004 | 2 | 0.010 |
Why?
| | Myenteric Plexus | 1 | 2004 | 4 | 0.010 |
Why?
| | Consanguinity | 1 | 2004 | 49 | 0.010 |
Why?
| | Aged | 1 | 2022 | 23729 | 0.010 |
Why?
| | Postpartum Period | 1 | 2005 | 336 | 0.010 |
Why?
| | Behavior, Animal | 1 | 2005 | 494 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2005 | 2045 | 0.010 |
Why?
| | Biopsy | 1 | 2004 | 1126 | 0.010 |
Why?
| | Ultrasonography | 1 | 2004 | 751 | 0.010 |
Why?
| | Rats, Sprague-Dawley | 1 | 2005 | 2481 | 0.010 |
Why?
| | Time Factors | 1 | 2010 | 6792 | 0.010 |
Why?
| | Rats | 1 | 2005 | 5628 | 0.010 |
Why?
| | Neurons | 1 | 2004 | 1583 | 0.010 |
Why?
| | Pregnancy | 1 | 2005 | 6731 | 0.010 |
Why?
|
|
Knupp's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|